VJOncology is committed to improving our service to you

BOPA/ISOPP 2019 | Minimizing the risk of steroid-induced hyperglycemia in NSCLC patients receiving immunotherapy

VJOncology is committed to improving our service to you

Islam Elkonaissi

Islam Elkonaissi, The Royal Marsden NHS Foundation Trust, London, UK, outlines the risk of developing hyperglycemia through steroid treatment in patients with non-small cell lung cancer treatment (NSCLC) who are receiving immunotherapy, and explains how we might minimize this risk. This interview took place at the International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium 2019, hosted by the British Oncology Pharmacy Association (BOPA), held in London, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter